低于说明书推荐剂量利伐沙班在亚洲NVAF患者中的研究进展

摘要/Abstract

摘要： 利伐沙班用于预防非瓣膜性房颤（non-valvular atrial fibrillation，NVAF）患者卒中已有明确的推荐剂量，但亚洲不同国家/地区批准用于NVAF患者卒中预防的利伐沙班推荐剂量存在差异。而且由于缺乏高证据级别的研究数据支持，目前亚洲相关研究对NVAF患者使用低于说明书推荐的利伐沙班剂量抗凝的有效性和安全性的评价存在不一致。本文对亚洲NVAF患者使用利伐沙班在各指南/共识中的应用剂量推荐、亚洲人群抗凝特点和临床研究现状等方面进行分析总结，为临床合理使用利伐沙班提供参考。

关键词: font-size:medium, ">利伐沙班；剂量；非瓣膜性房颤；抗凝

Abstract: There are clear recommended doses of Rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation， but the recommended dose of Rivaroxaban approved for stroke prevention in patients with NVAF varies in different Asian countries. Moreover， due to the lack of high-level evidence data， there are currently inconsistencies in the evaluation of the efficacy and safety of anticoagulation in patients with NVAF at doses of Rivaroxaban below the instructions recommended. This article analyzes and summarizes the dosage recommendation of Rivaroxaban in Asian NVAF patients in various guidelines/consensus， the anticoagulation characteristics of Asian population and the status of clinical research， so as to provide reference for the rational use of Rivaroxaban in clinical practice.

Key words: font-size:medium, ">Rivaroxaban； Dosage； Nonvalvular atrial fibrillation(NVAF)； Anticoagulant

中图分类号:

姚云娟, 张峻, 吴迪. 低于说明书推荐剂量利伐沙班在亚洲NVAF患者中的研究进展[J]. 中国药物评价, 2023, 40(3): 253-257.

YAO Yun-juan, ZHANG Jun, WU Di. Research Progress of Off-label Low-dose Rivaroxaban in Asian Patients with Non-valvular Atrial Fibrillation[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(3): 253-257.

参考文献

[1] 中华医学会心电生理和起搏分会，中国医师协会心律学专业委员会，中国房颤中心联盟心房颤动防治专家工作委员会.心房颤动：目前的认识和治疗建议(2021)[J]. 中华心律失常学杂志，2022，26(1)：15-88.
     [2] Chong D T， Andreotti F， Verhamme P， et al. Direct Oral Anticoagulants in Asian Patients with Atrial Fibrillation： Consensus Recommendations by the Asian Pacific Society of Cardiology on Strategies for Thrombotic and Bleeding Risk Management[J]. European cardiology， 2021，28（16）：e23.
     [3] Zhang J， Wang X， Liu X， et al. Comparative effectiveness and safety of direct acting oral anticoagulants in nonvalvular atrial fibrillation for stroke prevention： a systematic review and meta-analysis[J]. Eur J Epidemiol，2021，36(8)：793-812.
     [4] Lee SR， Lee YS， Park JS， et al. Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation[J]. Yonsei Med J，2019，60(3)：277-284.
     [5] Camm AJ， Cools F， Virdone S， et al. Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants[J]. J Am Coll Cardiol，2020，76(12)：1425-1436.
     [6] Shen NN， Zhang C， Hang Y， et al. Real-World Prevalence of Direct Oral Anticoagulant Off-Label Doses in Atrial Fibrillation： An Epidemiological Meta-Analysis[J]. Front Pharmacol， 2021，12：581293.
     [7] Chan YH， Chao TF， Chen SW， et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation[J]. Heart Rhythm， 2020，17(12)：2102-2110.
     [8] Qian J， Yan YD， Yang SY， et al. Benefits and Harms of Low-Dose Rivaroxaban in Asian Patients With Atrial Fibrillation： A Systematic Review and Meta-analysis of Real-World Studies[J]. Front Pharmacol， 2021， 12：642907.
     [9] Bayer AG.利伐沙班片说明书[EB/OL]. [2020-03-01]. www.http：//ypk.39.net/2309814/manual/.
     [10] 中华医学会心血管病学分会，中华医学会心电生理和起搏分会，中国医师协会心律学专业委员会.非瓣膜病心房颤动患者新型口服抗凝药的应用中国专家共识[J]. 中华心律失常学杂志， 2014， 18(5)： 321-329.
     [11] Hindricks G， Potpara T， Dagres N， et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)： The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC[J]. European Heart Journal，2021，42(5)：546-547
     [12] JCS Joint Working Group. Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013) [J]. Circ J，2014，78(8)：1997-2021.
     [13] Chiang CE， Wu TJ， Ueng KC， et al. 2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation[J]. J Formos Med Assoc， 2016， 115(11)：893-952.
     [14] Patel MR， Mahaffey KW， Garg J， et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med，2011， 365(10)：883-891.
     [15] 冠心病合并心房颤动患者抗栓管理中国专家共识[J]. 中华心血管病杂志，2020，48(7)：552-564.
     [16] Hori M， Matsumoto M， Tanahashi N， et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation-the J-ROCKET AF study [J]. Circ J， 2012， 76(9)：2104-2111.
     [17] Piccini JP， Hernandez AF， Zhao X， et al. Quality of care for atrial fibrillation among patients hospitalized for heart failure[J]. J Am Coll Cardiol， 2009， 54(14)：1280-1289.
     [18] Shi S， Tang Y， Zhao Q， et al. Prevalence and risk of atrial fibrillation in China： A national cross-sectional epidemiological study[J]. Lancet Reg Health West Pac， 2022， 23：100439.
     [19] Wang D， Li Y， Lee SG， et al. Ethnic differences in body composition and obesity related risk factors： study in Chinese and white males living in China[J]. PLoS One， 2011， 6(5)：e19835.
     [20] Wong KS， Hu DY， Oomman A， et al. Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial[J]. Stroke， 2014， 45(6)：1739-1747.
     [21] GBD 2016 Lifetime Risk of Stroke Collaborators， Feigin VL， Nguyen G， et al. Global， Regional， and Country-Specific Lifetime Risks of Stroke， 1990 and 2016[J]. N Engl J Med， 2018， 379(25)：2429-2437.
     [22] Lip GY， Wang KL， Chiang CE. Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation： time for a reappraisal[J]. Int J Cardiol， 2015， 180：246-254.
     [23] Chan YH， Chao TF， Chen SW， et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation[J]. Heart Rhythm， 2020， 17(12)：2102-2110.
     [24] Qian Y， Zhang J， Li J， et al. A retrospective study on the evaluation of the appropriateness of oral anticoagulant therapy for patients with atrial fibrillation[J]. PLoS One， 2021， 16(11)：e0259199.
     [25] Agnelli G， Gallus A， Goldhaber SZ， et al. Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939)： the ODIXa-DVT (oral direct Factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study[J]. Circulation， 2007， 116：180-187.
     [26] Buller HR， Lensing AW， Prins MH， et al. A dose-ranging study evaluating once-daily oral administration of the Factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis： the Einstein-DVT Dose-Ranging Study[J]. Blood， 2008， 112：2242-2247.
     [27] Tanigawa T， Kaneko M， Hashizume K， et al. Model-based dose selection for phase Ⅲ rivaroxaban study in Japanese patients with non-valvular atrial fibrillation[J]. Drug Metab Pharmacokinet， 2013， 28(1)：59-70.
     [28] Zhang F， Chen X， Wu T， et al. Population Pharmacokinetics of Rivaroxaban in Chinese Patients with Non-Valvular Atrial Fibrillation： A Prospective Multicenter Study[J]. Clin Pharmacokinet， 2022， 61(6)：881-893.
     [29] Liu XQ， Zhang YF， Ding HY， et al. Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation[J]. Acta Pharmacol Sin， 2022， 43(10)：2723-2734.
     [30] Zhao N， Liu Z， Xie Q， et al. A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard-or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation[J]. Front Pharmacol， 2022， 18(13)：814724.
     [31] Hou H， Li A， Zhang L， et al. Analysis of Effectiveness， Safety， and Bleeding Related to Rivaroxaban in Elderly Patients[J]. Clin Appl Thromb Hemost， 2020， 26：1076029620925923.
     [32] Halperin JL， Hankey GJ， Wojdyla DM， et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily， Oral， Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) [J]. Circulation， 2014， 130(2)：138-146.
     [33] 杨秋香，谢玲，武华军，等.利伐沙班用于超高龄非瓣膜性房颤患者的安全性评价[J]. 中国医院药学杂志，2022，42(24)：2660-2664.
     [34] Lai CL， Chen HM， Liao MT， et al. Dabigatran， Rivaroxaban， and Warfarin in the Oldest Adults with Atrial Fibrillation in Taiwan [J]. J Am Geriatr Soc， 2018， 66(8)：1567-1574.
     [35] 王倩，张丽，黄俊，等.利伐沙班在高龄非瓣膜性心房颤动患者中的常用剂量及预后分析[J]. 岭南心血管病杂志，2019，25(6)：638-641，646.
     [36] 张思婷. 80岁以上老年人应用利伐沙班的疗效及安全性分析[D]. 广州医科大学，2021.
     [37] Fox KA， Piccini JP， Wojdyla D， et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment[J]. Eur Heart J， 2011， 32(19)：2387-2394.
     [38] Hori M， Matsumoto M， Tanahashi N， et al. Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation： subanalysis of J-ROCKET AF for patients with moderate renal impairment[J]. Circ J， 2013， 77(3)：632-638.
     [39] 侯静怡，王梓凝，李昱熙，等.超高龄肾功能不全心房颤动患者抗凝治疗的病例分析[J]. 中国临床药理学杂志，2021，37(15)：2070-2076.
     [40] Atarashi H， Uchiyama S， Inoue H， et al. Ischemic stroke， hemorrhage， and mortality in patients with non-valvular atrial fibrillation and renal dysfunction treated with rivaroxaban： sub-analysis of the EXPAND study[J]. Heart Vessels， 2021， 36(9)：1410-1420.
     [41] Chan YH， Lee HF， Wang CL， et al. Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J-ROCKET AF Trials) in Asian Patients With Atrial Fibrillation[J]. J Am Heart Assoc， 2019， 8(21)：e013053.
     [42] 林莹，徐勇，郭新红，等.具有不同肌酐清除率水平的中国高龄非瓣膜性心房颤动患者应用利伐沙班的剂量选择研究[J]. 心血管病学进展，2019，40(8)：1176-1181.